Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Safety, Tolerability, and Pharmacokinetics Study of 2ccPA in Patients With Symptomatic Knee Osteoarthritis

NCT04229394 is registered in ClinicalTrials.gov with Orient Europharma Co., Ltd. as lead sponsor.

NCT NCT04229394
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04229394 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Safety, Tolerability, and Pharmacokinetics Study of 2ccPA in Patients With Symptomatic Knee Osteoarthritis
Lead sponsor
Orient Europharma Co., Ltd.
Phase
Phase 1
Overall status
Completed
Start date
February 13, 2018
Completion date
March 22, 2021
Enrollment
40 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

osteoarthritis (oa) of the knee